Where are Cochlear (ASX:COH) shares headed in 2022?

The hearing implant device maker has been a darling of long-term investors for decades. But is the stock too expensive now?

| More on:
An older woman tries to listen by cupping her ear.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Limited (ASX: COH) has been a staple for many ASX share portfolios in the past decade.

The hearing device maker has handsomely rewarded its original investors with a 2,350% return, according to Google Finance, and a 13.8% gain over 2021.

However, this year has ended on a sour note, as the share price actually has fallen more than 14% since its August high.

So where to from here? Is it one to buy for 2022?

'Sales have stagnated'

Redpoint Investment Management chief Max Cappetta told The Motley Fool that "revenue growth has faltered" recently for Cochlear.

"Implant sales have stagnated during the COVID pandemic."

Despite sound business prospects, Cappetta reckons that the valuation is "stretched" at the moment.

"Our metrics do point to a resurgence in revenue growth but this seems to be fully priced in at present," he said.

"While there are improving prospects going forward, there also remains the potential for competing products — though we note that the Cochlear's devices remain clear market leaders."

Cochlear shares are dividing the experts

It seems Cochlear shares are polarising analysts.

The Motley Fool's Zach Bristow reported earlier this month that out of 4 major investment houses, one is bearish, one is neutral and two are slightly bullish on the stock.

Goldman Sachs has set a target of $197 a share, which is about a 10% downside from Wednesday morning's price of $218.18.

"The firm says that Cochlear's surgery volumes remain at risk due to their elective nature. It notes that Australian surgery numbers are yet to recover to pre-pandemic volumes," Bristow reported.

"Goldman Sachs recognises these challenges and reckons Cochlear is a sell in a recent note to clients."

Meanwhile Citi is neutral with a $220 target, while Jarden and Macquarie rate Cochlear as a "buy" with targets of $258 and $256 respectively.

According to CMC Markets, 8 of 12 analysts are recommending a "hold" for Cochlear shares as the year winds down.

Motley Fool contributor Tony Yoo owns Cochlear Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three happy girls on jumping motion with inflatable mattresses at the beach.
Share Gainers

3 ASX All Ords shares leading the charge in 2025

These ASX All Ords shares have soared 16% to 37% already in 2025.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

3 ASX 200 healthcare stocks with 'strong return potential' in 2025

A leading investment manager expects 2025 will be a good year for these ASX 200 healthcare companies.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Why are Mesoblast shares in a trading halt?

The biotech company requested a trading halt before the market open on Friday. Here's why.

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

ASX All Ords stock rockets 18% on FDA clearance

This stock is making very healthy returns on US news.

Read more »

rising medical asx share price represented by excited doctors dancing in ward
Healthcare Shares

Up 77% in a month! What's going on with the Mesoblast share price?

This stock has blown the lights out in recent weeks...

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Guess which ASX healthcare stock is up 31% on big news

What is getting investors excited on Tuesday? Let's find out.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

Healthy gains: 5 best ASX 200 healthcare shares of 2024

Four of the five best-performing ASX 200 healthcare stocks of 2024 more than doubled in value.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Why did the CSL share price go backwards in 2024?

CSL shares closed out 2024 in the red. But why?

Read more »